公开(公告)号：EP1334120B1

公开(公告)日：2012-04-11

申请号：EP01996547.4

申请日：2001-11-16

申请人： ALLERGAN, INC.

发明人： STEWARD, Lance, E. ,  SPANOYANNIS, Athena ,  LIN, Wei-Jen ,  AOKI, Kei, Roger

IPC分类号： C07K14/33

CPC分类号： C12Y304/24069 ,  A61K38/00 ,  C12N9/52

摘要： The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins and the modification involves one or more secondary modification sites. In a BoNT/E (Botilunum Toxin serotype E) derivative, the N-terminal myristylation site GVDIAY is fused to position 15 of the BoNT/E light chain. In a BoNT/A derivative the N-terminal myristylation site GLEVSF at position 254 is deleted. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hiperhidrosis, and pain.

公开(公告)号：EP1718756B1

公开(公告)日：2011-11-16

申请号：EP05724048.3

申请日：2005-02-23

申请人： ALLERGAN, INC.

发明人： FERNANDEZ-SALAS, Ester ,  GARY, Patton, E. ,  AOKI, Kei, Roger

IPC分类号： C12Q1/00

CPC分类号： G01N33/56911 ,  G01N2333/50

摘要： Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.

公开(公告)号：EP0889731B1

公开(公告)日：2004-11-24

申请号：EP97916168.4

申请日：1997-03-20

申请人： Allergan, Inc.

发明人： AOKI, Kei, Roger ,  WHEELER, Larry, A. ,  GARST, Michael, E.

IPC分类号： A61K38/16

CPC分类号： G01N33/5088 ,  A61K38/1703 ,  A61K38/4893 ,  G01N2800/10 ,  A61K2300/00

摘要： A method for administration of botulinum toxin, includes the steps of (a) selecting at least one neuromuscular blocking agent having a duration of activity shorter than neuromuscular blocking activity of botulinum toxin; (b) selecting at least one muscle of a muscle group; (c) intramuscularly injecting the selected agent into the selected muscle; (d) observing muscle relaxation in both the selected muscle and other non-selected muscles in the muscle group to determine spill-over, muscle tone and balance; (e) repeating steps (b) - (d) until a final muscle selection is found; and (f) intramuscularly injecting botulinum toxin into the final muscle selection.

公开(公告)号：EP1381677A2

公开(公告)日：2004-01-21

申请号：EP01989807.1

申请日：2001-11-27

申请人： Allergan, Inc.

发明人： LIN, Wei-Jen ,  AOKI, Kei, Roger ,  STEWARD, Lance, E.

IPC分类号： C12N9/52 ,  C07K14/33

CPC分类号： C07K14/33 ,  A61K38/00 ,  Y02A50/469

摘要： Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.

公开(公告)号：EP1322324A2

公开(公告)日：2003-07-02

申请号：EP01966482.0

申请日：2001-08-31

申请人： Allergan, Inc.

发明人： BROOKS, Gregory, F. ,  AOKI, Kei, Roger

IPC分类号： A61K38/48 ,  A61P21/00

CPC分类号： A61K38/4893 ,  A61K39/08 ,  A61K2039/54

摘要： Methods for treating an injured muscle by local administration of a neurotoxin, such as a botulinum toxin, to promote healing and/or to reduce the pain associated with an injured muscle.

公开(公告)号：EP2271670B1

公开(公告)日：2014-09-03

申请号：EP09719709.9

申请日：2009-03-13

申请人： ALLERGAN, INC.

发明人： FERNANDEZ-SALAS, Ester ,  WANG, Joanne ,  GARAY, Patton, E. ,  WONG, Lina, S. ,  HODGES, D., Dianne ,  AOKI, Kei, Roger

IPC分类号： C07K16/12 ,  G01N33/569

CPC分类号： C07K16/1282 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  C12Q1/37 ,  G01N33/5014 ,  G01N33/566 ,  G01N33/6854

公开(公告)号：EP2464367A2

公开(公告)日：2012-06-20

申请号：EP10760808.5

申请日：2010-08-16

申请人： Allergan, Inc.

发明人： JACKY, Birgitte, P.S. ,  GARAY, Patton, E. ,  MOLINA, Yanira ,  STATHAKIS, Dean, G. ,  FRANCIS, Joseph ,  AOKI, Kei, Roger ,  FERNANDEZ-SALAS, Ester ,  HUNT, Terrence J. ,  STEWARD, Lance, E. ,  GHANSHANI, Sanjiv

IPC分类号： A61K38/00 ,  A61P35/00

CPC分类号： A61K38/164 ,  A61K38/4893

摘要： The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.

公开(公告)号：EP2271670A1

公开(公告)日：2011-01-12

申请号：EP09719709.9

申请日：2009-03-13

申请人： Allergan, Inc.

发明人： FERNANDEZ-SALAS, Ester ,  WANG, Joanne ,  GARAY, Patton, E. ,  WONG, Lina, S. ,  HODGES, D., Dianne ,  AOKI, Kei, Roger

IPC分类号： C07K16/12 ,  G01N33/569

CPC分类号： C07K16/1282 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  C12Q1/37 ,  G01N33/5014 ,  G01N33/566 ,  G01N33/6854

摘要： The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P
1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P
1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing α-BoNT/A antibodies.

公开(公告)号：EP2211890A1

公开(公告)日：2010-08-04

申请号：EP08841644.1

申请日：2008-10-21

申请人： ALLERGAN, INC.

发明人： BRIN, Mitchell, F. ,  FRANCIS, Joseph ,  AOKI, Kei, Roger

IPC分类号： A61K38/16 ,  A61K35/74 ,  A61P13/10

CPC分类号： A61K38/16

摘要： The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such modified Clostridial toxins and compositions.

公开(公告)号：EP2038299A2

公开(公告)日：2009-03-25

申请号：EP07812774.3

申请日：2007-07-11

申请人： ALLERGAN, INC.

发明人： STEWARD, Lance, E. ,  FRANCIS, Joseph ,  FERNANDEZ-SALAS, Ester ,  GILMORE, Marcella, A. ,  LI, Shengwen ,  AOKI, Kei, Roger

IPC分类号： C07K14/33

CPC分类号： C07K14/33 ,  C07K2319/00 ,  C07K2319/50 ,  C07K2319/55

摘要： The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.